Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2009. The report specifically addresses a notifiable share interest change in Addex Pharmaceuticals Ltd, a Swiss-based allosteric modulation company.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for GSK. The only quantitative data presented relates to the specific equity transaction with Addex Pharmaceuticals Ltd:
- Shares Sold: 2,596 shares by S.R. One, Limited (a wholly owned US subsidiary of GSK).
- Remaining Interest: 290,529 shares.
- Ownership Percentage: 4.95% of Addex (based on 5,862,492 total shares outstanding).
- Threshold Trigger: The sale caused GSK's interest to fall below the 5% disclosure threshold required by the SWX Swiss Exchange Act.
Material Changes
The material change reported is the reduction of GSK's equity stake in Addex Pharmaceuticals Ltd from above 5% to 4.95%. This reduction was triggered by the sale of 2,596 shares on December 2, 2009. The filing explicitly states that GSK is not a primary insider in Addex.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies regarding GSK's broader operations. The document is strictly a regulatory notification of the shareholding change in Addex.
Key Facts for Investor Verification
- Verify the current market price of Addex Pharmaceuticals Ltd shares on the SWX Swiss Exchange to assess the monetary value of the 2,596 shares sold.
- Confirm whether the 4.95% stake represents a strategic exit or a routine portfolio adjustment for GSK.
- Note that this filing does not contain GSK's quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.